SCHEDULE 13G 0001757283 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 11/07/2025 0002044725 EVOMMUNE, INC. 30054Y107 1841 Page Mill Road, Suite 100 Palo Alto CA 94304 Rule 13d-1(c) Andera Partners I0 0.00 1897362.00 0.00 1897362.00 1897362.00 6.0 OO BioDiscovery 6 FPCI I0 0.00 1897362.00 0.00 1897362.00 1897362.00 6.0 OO Stephane Bergez I0 0.00 1897362.00 0.00 1897362.00 1897362.00 6.0 IN Francois Xavier Mauron I0 0.00 1897362.00 0.00 1897362.00 1897362.00 6.0 IN EVOMMUNE, INC. 1841 Page Mill Road, Suite 100, Palo Alto, CA, 94304. The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. 2 place de Rio de Janeiro 75008 Paris France BioDiscovery 6 France Andera France Bergez France Mauron France Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. BioDiscovery 6 is the record holder of 1,897,362 shares of common stock. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. The percentage set forth in each row 11 is based upon 31,483,810 shares outstanding as of November 7, 2025, as reported in the Issuer's final prospectus dated November 5, 2025 filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of the date hereof and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement Andera Partners /s/ Stephane Bergez 11/17/2025 BioDiscovery 6 FPCI /s/ Stephane Bergez 11/17/2025 Stephane Bergez /s/ Stephane Bergez 11/17/2025 Francois Xavier Mauron /s/ Francois Xavier Mauron 11/17/2025